Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference

Rhea-AI Summary

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, will participate in the 2022 Virtual Growth Conference from March 28-30. CEO Kathy Lee-Sepsick will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 from 3:00 pm to 4:30 pm ET. The conference will discuss innovations in women's health, highlighting Femasys's ongoing development of minimally invasive technologies, including FemBloc® and FemaSeed® for permanent birth control and infertility treatment respectively. For more details, registration is available online.

ATLANTA, March 25, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company will participate in a panel at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and M-Vest, being held March 28th – 30th from 9:00 am – 5:30 pm ET.

During this on-demand virtual conference, Kathy Lee-Sepsick, Founder, President and Chief Executive Officer, will participate in the panel detailed below:

Panel title: “Advances in Women's Health: From Clinical to Commercial.”
Panel Description: From the bench to commercial, advances in the women’s health category are expanding available options and unlocking opportunities.
Panel day/ time: Monday, March 28^th from 3:00 pm – 4:30 pm ET

To register and listen to the panel discussion, sign up here.

About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, is currently marketed in the United States. Femasys is also advancing FemCerv^®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com

Femasys Inc.
Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com

FAQ

What is Femasys participating in on March 28, 2022?

Femasys is participating in the 2022 Virtual Growth Conference, specifically in a panel discussion on advances in women's health.

Who will represent Femasys at the conference?

Kathy Lee-Sepsick, the Founder, President, and CEO of Femasys, will represent the company.

What is the focus of the panel discussion involving Femasys?

The panel titled 'Advances in Women's Health: From Clinical to Commercial' will explore innovations and opportunities in women's health.

When is Femasys's panel discussion scheduled?

The panel discussion is scheduled for March 28, 2022, from 3:00 pm to 4:30 pm ET.

How can I register to listen to Femasys's panel at the conference?

You can register and listen to Femasys's panel discussion by signing up through the official conference website.